Which myelofibrosis patients benefit from treatment with ruxolitinib? A single-center experience

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10503476" target="_blank" >RIV/00179906:_____/25:10503476 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/25:10503476
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kgB.snMp-s" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kgB.snMp-s</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5114/aoms/209001" target="_blank" >10.5114/aoms/209001</a>

Result language
angličtina
Original language name
Which myelofibrosis patients benefit from treatment with ruxolitinib? A single-center experience
Original language description
We analyzed 54 patients with myelofibrosis treated with ruxolitinib at our center, focusing on its impact on constitutional symptoms and splenomegaly. Constitutional symptoms improved in 96.3% of patients within the first six weeks of therapy, while a reduction in spleen size was observed in 75.9% of cases. Importantly, our findings demonstrate that any degree of splenic response is associated with prolonged overall survival.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)